(Total Views: 97)
Posted On: 12/15/2022 8:20:46 AM
Post# of 25095
$RIGL News Article - Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes https://marketwirenews.com/news-releases/rige...91134.html
(0)
(0)
My Twitter: WhyteStocks
Scroll down for more posts ▼
